GlassScriptPhysician profile
Jonathan P Pezanoski
NPI 1053355545
$3,070.71
in general payments reported to CMS, 2019-2025
19 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $126 · 2021: $63.94 · 2022: $412 · 2023: $524 · 2024: $446 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,995.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,135.19 | 2019-2025 | |
| Boston Scientific Corporation | $626.65 | 2019-2024 | Spyglass Discover, Resolution 360 Ultra Clip, Watchman Flx |
| Janssen Biotech, INC. | $265.80 | 2024-2025 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $189.31 | 2025 | Iqirvo, Bylvay |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.89 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $109.84 | 2021-2025 | Entyvio, Eohilia |
| Cook Medical LLC | $109.26 | 2019 | |
| Janssen Scientific Affairs, LLC | $108.80 | 2019 | |
| Aimmune Therapeutics, INC. | $80.26 | 2025 | Vowst |
| Olympus America INC. | $78.77 | 2023-2024 | Endoclot Phs, Visiglide, Single Use Aspiration Needle Na-U200h |
| Genzyme Corporation | $67.93 | 2022-2025 | |
| Apollo Endosurgery US INC | $37.98 | 2023 | Overstitch Endoscopic Suturing System |
| Pfizer INC. | $36.38 | 2025 | |
| Biocon Biologics INC | $27.24 | 2025 | Yesintek |
| Tersera Therapeutics LLC | $23.79 | 2025 | Xermelo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $19.38 | 2023 | Ocaliva |
| Chiesi USA, INC. | $17.74 | 2025 | Cleviprex |
| Lilly USA, LLC | $13.79 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $11.71 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Pezanoski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.